MTOR and interstitial lung disease: In conclusion, our research reinforces the complex and potentially fatal nature of mTOR inhibitor-induced ILD and highlights the need to include drug-induced ILD in the differential diagnosis of pulmonary conditions in transplant recipients receiving mTOR inhibitor therapy.